Title: Updates of phramacoherapy of diabetes mellitus

Biography:

Dr. Suzan has completed her MSc from faculty of pharmacy, Alexandria university, egypt. Ph D in pharmacology from strathclyde university, Uk. acted as professor of pharmacology in faculty of medicine, Alexandria university, egypt from 1988 to 2003. She  acted as a Head of the Department in the same University until 2005. She is now Emeritus professor in pharmacology, Faculty of Medicine, Egypt.

Publishe 35 papers in reputed Journals and supervised 14 PhD thesis, now elected as President of Egyptian Association of advancement of Basic Medical Sciences

Abstract

Despite the known benefits of a healthy life style, many individuals finds it hard to maintain such a life style in the modern world, which facilitates sedentary behavior and overeating. Consequently, the prevalence of  Type-II Diabetes mellitus is predict to increase dramatically over the coming years. To counteract the resulting impact on morbidity and motality of the disease, a tremendous number of new Treatments available for diabetes was poured in to the market research lines in diabetes can be grouped in to three main categories: Technological, Biological and pharmacological with the latter category, pharmacological research appears the most effective for significantly reducing the burden of Type-II Diabetes. However the success of antibiotic medication has also been limited by their mechanism of action and side effects. A big number of promising new drugs were developed to acheive newer antidiabetic medication including oral insulin, gene therapy, the incretins, di-peptidyl peptidase-4 inhibitors, peroxisome prolifirator-activated receptor inhibitors and sodium glucose co-transporter inhibitors to treat Type-II Diabetes. However the up to date, the standard of care for diabetes management is not enough for long run benefits to diabetic patients. The aim of my talk is to provide a brief overview of current anti-diabetic drugs & updates on diabetes management for clinical usage.